GRAMLGTHTMEVTV

a glycoprotein 100-derived melanoma peptide that contains overlapping human leukemic antigen A2-, DR53-, and DQw6-restricted T-cell epitopes for treatment of patients with stage IV melanoma

Also Known As:

Networked: 1 relevant articles (1 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Celis, Esteban: 1 article (07/2007)
2.	Melanoma Study Group of the Mayo Clinic Cancer Center: 1 article (07/2007)

Related Diseases

1.

Melanoma (Melanoma, Malignant) 07/01/2007 - "In this report, the authors present the results from a clinical trial that evaluated the safety and immunologic efficacy of the MPS160 vaccine in patients with metastatic melanoma. " 07/01/2007 - "Patients with stage IV melanoma were randomized to 1 of 3 treatment arms: 1) MPS160 in incomplete Freund adjuvant (Montanide ISA-51); 2) MPS160 in Montanide ISA-51 with 75 microg of granulocyte-macrophage-stimulating factor (GM-CSF); or 3) MPS160 in Montanide ISA-51 with 100 microg of GM-CSF. " 07/01/2007 - "MPS160 (GRAMLGTHTMEVTV) is a glycoprotein 100-derived melanoma peptide that contains overlapping human leukemic antigen A2-, DR53-, and DQw6-restricted T-cell epitopes. "

Related Drugs and Biologics

1.	Vaccines
2.	GRAMLGTHTMEVTV
3.	T-Lymphocyte Epitopes (Epitopes, T Lymphocyte)
4.	Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)
5.	Peptides (Polypeptides)
6.	Glycoproteins (Glycoprotein)
7.	Freund's Adjuvant
8.	Antigens
9.	montanide ISA 51